<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03210519</url>
  </required_header>
  <id_info>
    <org_study_id>CS15036</org_study_id>
    <nct_id>NCT03210519</nct_id>
  </id_info>
  <brief_title>To Evaluate the Efficacy of Eleutherococcus Senticosus for Subjects Under Renal Dialysis</brief_title>
  <official_title>A Randomized, Double-blind, Placebo-controlled Trial to Evaluate the Efficacy of Eleutherococcus Senticosus for Anti-inflammation and Improvement of Erythropoietin Hyporesponsiveness in Subjects Under Renal Dialysis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Chung Shan Medical University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Chung Shan Medical University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a randomized, double-blind, placebo-controlled, parallel comparison trial to evaluate
      the efficacy and safety of Eleutherococcus Senticosus taken orally by patients under regular
      dialysis. Eligible subjects with written consent were randomized into one of the two groups:
      A. Acanthopanax senticosus (30mg/vial); B. Placebo. After 2-4 weeks of run-in period, the
      study subjects were asked to take the investigational products orally for 90 days in order to
      evaluate the effects of oral Eleutherococcus Senticosus liquid on the markers of
      inflammation, anemia, and safety, and to compare the efficacy among oral Acanthopanax
      senticosus and placebo.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">December 9, 2015</start_date>
  <completion_date type="Actual">June 30, 2017</completion_date>
  <primary_completion_date type="Actual">June 30, 2017</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Erythropoietin (EPO)</measure>
    <time_frame>baseline, at 1 month, at 2 months, at 3 months</time_frame>
    <description>Monthly dose</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Hb</measure>
    <time_frame>baseline, at 1 month, at 2 months, at 3 months</time_frame>
    <description>Hemoglobin</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>RBC</measure>
    <time_frame>baseline, at 1 month, at 2 months, at 3 months</time_frame>
    <description>Red Blood Cell</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hct</measure>
    <time_frame>baseline, at 1 month, at 2 months, at 3 months</time_frame>
    <description>Hematocrit</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>MCHC</measure>
    <time_frame>baseline, at 1 month, at 2 months, at 3 months</time_frame>
    <description>Mean corpuscular hemoglobin concentration</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>MCV</measure>
    <time_frame>baseline, at 1 month, at 2 months, at 3 months</time_frame>
    <description>Mean corpuscular volume</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>MCH</measure>
    <time_frame>baseline, at 1 month, at 2 months, at 3 months</time_frame>
    <description>Mean Corpuscular Hemoglobin</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>iPTH</measure>
    <time_frame>baseline and at 3 months</time_frame>
    <description>Intact Parathyroid Hormone</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>TNF-alpha</measure>
    <time_frame>baseline and at 3 months</time_frame>
    <description>Tumor necrosis factor - alpha</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>IL-6</measure>
    <time_frame>baseline and at 3 months</time_frame>
    <description>Interleukin 6</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">19</enrollment>
  <condition>Renal Dialysis</condition>
  <arm_group>
    <arm_group_label>Eleutherococcus senticosus</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Acanthopanax senticosus-mono formula (30mg/vial) and Fructus Ziziphi Jujube concentrated juice15ml/vial</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Fructus Ziziphi Jujube concentrated juice15ml/vial</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Eleutherococcus senticosus</intervention_name>
    <description>taken orally once/day for 90 days</description>
    <arm_group_label>Eleutherococcus senticosus</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>taken orally once/day for 90 days</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Under regular dialysis for at least 3 months

          -  Hemoglobin (Hb) &lt;11 g/L after regular Erythropoietin (EPO) treatment

          -  Subjects with written informed consent form

        Exclusion Criteria:

          -  Use of steroid or high dose of antiplatelet drug (e.g. Aspirin &gt;300mg) within one
             month

          -  Had surgery, myocardial infarction, or tumor within 12 weeks

          -  Currently use of antibiotic treatment for acute infection

          -  Pregnant women

          -  Reticulocyte&gt;40 x 10^9

          -  Anemia (ferritin &lt;100ng/mL and Transferrin Saturation (TSAT) &lt;20%)

          -  Urea reduction ratio &lt;65% or single pool Kt/V &lt; 1.0 (hemodialysis patients) or total
             weekly Kt/V&lt;1.7 (peritoneal dialysis patients)

          -  Sudden change of eating habit within one month

          -  Expected life less than six months or with unstable medical conditions

          -  Known history of allergic reaction to the investigational products

          -  With acute diseases and judged by the investigator to be ineligible to participate

          -  Received melatonin, androgen therapy or blood transfusion within two months

          -  Received any trial medications within 30 days
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Nae-Cherng Yang, Ph. D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Chun Shan Medical University</affiliation>
  </overall_official>
  <verification_date>July 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 3, 2017</study_first_submitted>
  <study_first_submitted_qc>July 4, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">July 7, 2017</study_first_posted>
  <last_update_submitted>July 4, 2017</last_update_submitted>
  <last_update_submitted_qc>July 4, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">July 7, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Chung Shan Medical University</investigator_affiliation>
    <investigator_full_name>Nae-Cherng Yang</investigator_full_name>
    <investigator_title>Associate Professor</investigator_title>
  </responsible_party>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

